Jco precision oncology.
For this reason, JCO Precision Oncology has organized this special series of tutorial and review articles on statistical methods for precision oncology that will serve as a bridge between the clinical researcher and statistician communities, will help facilitate the application of new methods, and will stimulate the development of more and ...
DOI: 10.1200/PO.18.00401 JCO Precision Oncology - published online June 20, 2019 Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non–Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based ResultsThe increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor gene sequencing panels have made this a challenging time for ...DOI: 10.1200/PO.19.00339 JCO Precision Oncology no. 4 (2020) 239-243. Published online March 27, 2020. PMID: 35050735. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA Assay David J. Einstein, MD 1. x. David J. Einstein. Search for articles by this author ...The American Society of Clinical Oncology explains that the end stage of cancer is diagnosed when the cancer has spread to other parts of the body. This stage is also called stage 4, advanced or metastatic cancer.Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …
Supported by The Cholangiocarcinoma Foundation (to M.Y.), the National Cancer Institute Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancers (P50 CA062924), the NIH Center Core Grant (P30 CA006973), and the American Society of Clinical Oncology Career Development Award.Mar 9, 2022 · This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines
Jan 8, 2021 · DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017May 18, 2021 · As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ... PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 insertion mutations are emerging as a distinct molecular subtype with expanding therapeutic options. We describe the molecular epidemiology and genomic features of HER2-altered NSCLC in an Asian tertiary cancer center. METHODS ...DOI: 10.1200/PO.20.00495 JCO Precision Oncology no. 5 (2021) 1122-1132. Published online July 9, 2021. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review Kara L. Larson, PhD …Web
31 Aug 2022 ... Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. 2017;2017.
Nov 12, 2022 · PURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ...
DOI: 10.1200/PO.18.00325 JCO Precision Oncology - published online June 13, 2019OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic …JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not accepted for publication for reasons of priority. Such papers may be more appropriate for an oncology specialty journal such as JCO PO. In that regard, JCO PO 's new program will ...PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ...DOI: 10.1200/PO.19.00172 JCO Precision Oncology - published online September 20, 2019 PMID: 32923866. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia Roberta La Starza, MD, PhD 1. x. Roberta La Starza. Search for articles by this author ...
Jan 12, 2023 · PURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS We developed and implemented a precision oncology decision support system, GI TARGET ... DOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021) 510-524. Published online March 19, 2021. Published online March 19, 2021. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyWebDOI: 10.1200/PO.18.00028 JCO Precision Oncology - published online October 19, 2018WebAug 5, 2021 · DOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling DOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ...
Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017
DOI: 10.1200/PO.20.00069 JCO Precision Oncology no. 4 (2020) 665-679. Published online June 16, 2020. Published online June 16, 2020. BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerJCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.Regrettably, the proportion of patients with advanced cancer outstrip the specialty PC workforce capacity. 20 In the United States, there are currently about 1,700-3,300 full-time equivalents of board-certified PC specialists, most of whom are not oncology-specific, and care for patients with other serious illness. 21,22 Unfortunately, the current pipeline for future PC physicians is narrow ...DOI: 10.1200/PO.18.00414 JCO Precision Oncology no. 4 (2020) 557-569. Published online June 1, 2020. PMID: 32923885. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients Jingyu Cao, MD 1. x. Jingyu Cao. Search for articles by this author; Jing ...DOI: 10.1200/PO.21.00437 JCO Precision Oncology no. 6 (2022) e2100437. Published online January 27, 2022. Published online January 27, 2022. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature …DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994WebJCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other …
PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are ...
Apr 7, 2023 · DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812
DOI: 10.1200/PO.22.00258 JCO Precision Oncology no. 7 (2023) e2200258. Published online January 30, 2023. PMID: 36716415. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial Eric Pujade-Lauraine, MD 1. x. …Precision oncology, where patients are given therapies on the basis of their genomic profile and disease trajectory, is rapidly evolving to become a pivotal part of cancer management, supported by the approval of many biomarker-matched targeted therapies and cancer immunotherapies by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 1 Driven by recent advances in ...24-hour private clinics and medical centers 49 Ambulatory surgery in Tashkent, in Uzbekistan 4 Analyses of blood by rubella - services 3 Analysis of allergy - services 7 …DOI: 10.1200/PO.20.00325 JCO Precision Oncology no. 5 (2021) 442-449. Published online February 24, 2021. Published online February 24, 2021. GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific MortalityPURPOSE Precision medicine uses advanced molecular techniques to guide the use of targeted therapeutic drugs and is an emerging paradigm in pediatric oncology. Clinical evidence related to the efficacy of many novel targeted drugs, however, is currently very limited given the rarity of pediatric cancer and the lack of published evidence for the use of these drugs in children. This systematic ...Key Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ... OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.Jun 29, 2023 · Cutaneous melanoma (CM) is the fifth most common cancer in the United Sates, with an estimated 99,780 new cases diagnosed in 2022. 1 Prognostic biomarkers aim to identify patients at high or low risk of disease progression to align treatment decisions with the risk of poor outcomes. 2,3 For CM, the most well-established prognostic markers outlined by the American Joint Committee on Cancer ... Aug 19, 2021 · DOI: 10.1200/PO.20.00472 JCO Precision Oncology no. 5 (2021) 1312-1324. Published online August 19, 2021. Published online August 19, 2021. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples PURPOSE Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although these phases are necessary to achieve remission, the primary chemotherapeutic agents have potentially serious toxicities, which may lead to delays or discontinuations of therapy. The ...DOI: 10.1200/PO.21.00510 JCO Precision Oncology no. 6 (2022) e2100510. Published online June 8, 2022. PMID: 35675577. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures Kabir Mody, MD 1. x. Kabir Mody. Search for articles by this author; ...WebDOI: 10.1200/PO.20.00525 JCO Precision Oncology no. 5 (2021) 779-791. Published online May 5, 2021. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative Rachel Pearlman, MS 1. x. Rachel Pearlman. Search for articles by this author ...
Looking for TASHKENT CITY ONCOLOGICAL DISPENSER. in Tashkent? - ☎️Phones ⚑Location of the company on the map, search for directions, how to get …JCO Precision Oncology 10.1200/PO.17.00071 (2017). Google Scholar. Yoshida, G.J. Applications of patient-derived tumor xenograft models and tumor organoids ...The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of …WebInstagram:https://instagram. top hydrogen stocksetf for restaurantshow to start day tradingavantax cetera A fellow M.D. is a medical doctor who has been given a fellowship, which is a residency that teaches doctors a sub-specialty, such as internal medicine, movement disorders, gynecologic oncology and pediatric hematology, according to the Uni... aiq holdingstop online mortgage companies JCO Precision Oncology, 2022 Aug 11. PMID: 35952319; Storrs EP, Usmani A, Chati P, Sloan I, Krasnick BA, Babbra R, Harris PK, Qaium F, Chatterjee D, Wetzel C ... top healthcare reits DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017DOI: 10.1200/PO.23.00261 JCO Precision Oncology no. 7 (2023) e2300261. Published online October 12, 2023. PMID: 37824797. Computational Advancements in Cancer Combination Therapy Prediction Victoria L. Flanary, BS 1. x. Victoria L. Flanary. Search for articles by this author ...Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP… ... EACH PATIENT IS NOTABLE AND CAN BENEFIT FROM A PREDICTIVE PRECISION MEDICINE ...